Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515419 | 0.92 | SLC6A9 (0.53) | SLC6A9RAB9AATMKMT2AHPGD | |
| SCHEMBL382359 | 0.91 | SLC6A9 (0.61) | SLC6A9RAB9AATMKMT2AHPGD | |
| SCHEMBL514551 | 0.91 | SLC6A9 (0.52) | SLC6A9RAB9AATMKMT2AHPGD | |
| SCHEMBL2605270 | 0.81 | SLC6A9 (0.64) | SLC6A9RAB9AATMKMT2ANPC1 | |
| SCHEMBL514230 | 0.77 | SLC6A9 (0.51) | SLC6A9 | |
| SCHEMBL3704810 | 0.77 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7894785 | 0.77 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL3788018 | 0.77 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL2123074 | 0.77 | SLC6A9 (0.76) | SLC6A9RAB9AATMKMT2A | |
| SCHEMBL2605316 | 0.77 | SLC6A9 (0.76) | SLC6A9RAB9AATMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-02-02 | — | — | US | claimed |
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, C1S | SLC6A9 1683/4885RAB9A 2459/4885ATM 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.